To determine the safety and feasibility of the auditory brainstem implant (ABI) in congenitally deaf children with cochlear aplasia and/or cochlear nerve deficiency.
Phase I feasibility clinical trial of surgery in 10 children, ages 2 to 5 years, over a 3-year period.
Tertiary children's hospital and university-based pediatric speech/language/hearing center.
ABI implantation and postsurgical programming.
The primary outcome measure is the number and type of adverse events during ABI surgery and postsurgical follow-up, including behavioral mapping of the device. The secondary outcome measure is access to and early integration of sound.
To date, nine children are enrolled. Five children have successfully undergone ABI surgery and postoperative behavioral programming. Three children were screen failures, and one child is currently undergoing candidacy evaluation. Expected adverse events have been documented in three of the five children who received the ABI. One child experienced a cerebral spinal fluid leak, which resolved with lumbar drainage. One child demonstrated vestibular side effects during device programming, which resolved by deactivating one electrode. One child experienced postoperative vomiting resulting in an abdominal radiograph. Four children have completed their 1-year follow-up and have speech detection thresholds of 30 to 35 dB HL. Scores on the IT-MAIS/MAIS range from 8 to 31 (out of a total of 40), and the children are demonstrating some ability to discriminate between closed-sets words that differ by number of syllables (pattern perception).
ABI surgery and device activation seem to be safe and feasible in this preliminary cohort.
Supplemental Digital Content is available in the text
*House Clinic/Huntington Medical Research Institutes
†Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine of the University of Southern California
‡Children's Hospital of Los Angeles, Los Angeles, California
Address correspondence and reprint requests to Eric P. Wilkinson, M.D., House Clinic and Huntington Medical Research Institutes, 2100 W. Third St. #111, Los Angeles, CA; E-mail: email@example.com
The Los Angeles Pediatric ABI Team: House Clinic/Huntington Medical Research Institutes: Eric P. Wilkinson, M.D.; Marc S. Schwartz, M.D.; Children's Hospital of Los Angeles: Mark D. Krieger, M.D.; Tena L. Rosser, M.D.; Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine of the University of Southern California: Laurie S. Eisenberg, Ph.D.; Laurel M. Fisher, Ph.D.; Jamie L. Glater, Au.D.; Dianne Hammes Ganguly, M.A.; Amy S. Martinez, M.A.; Debra K. Schrader, B.S.; Robert V. Shannon, Ph.D.; Margaret Winter, M.S.; Team Consultants: Danielle Dzubak, Au.D.; Carren J. Stika, Ph.D.
The team discloses research support (ABI devices) from Cochlear Americas for this research study: The clinical trial is supported by NIH Grant #U01DC013031 (NIDCD). IRB CHLA #CCI-13-00094, ClinicalTrials.gov #NCT02102256.
The authors disclose no conflicts of interest.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://journals.lww.com/otology-neurotology).